Pictet Asset Management (Switzerland)’s Denali Therapeutics DNLI Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$30.3M	Sell	1,027,977 -220,513	-18%	-$6.2M	0.04%	373
2023 Q1	$28.8M	Buy	1,248,490 +77,134	+7%	+$2.12M	0.04%	380
2022 Q4	$32.6M	Buy	1,171,356 +168,171	+17%	+$5M	0.05%	340
2022 Q3	$30.8M	Sell	1,003,185 -11,973	-1%	-$389K	0.05%	348
2022 Q2	$29.9M	Sell	1,015,158 -8,405	-0.8%	-$220K	0.04%	379
2022 Q1	$32.9M	Buy	1,023,563 +24,943	+2%	+$858K	0.04%	392
2021 Q4	$44.5M	Buy	998,620 +130,117	+15%	+$6.16M	0.04%	361
2021 Q3	$43.8M	Buy	+868,503	New	+$48.9M	0.05%	361

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s DNLI Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Denali Therapeutics (DNLI) stake by 18% in Q2 2023, selling an estimated $6.2M and leaving 1,027,977 shares worth $30.3M. The position accounts for 0.04% of the portfolio, ranked #373.

Pictet Asset Management (Switzerland) first reported a position in DNLI in Q3 2021 and has held it in 8 quarters since. The position peaked at $44.5M in Q4 2021. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2023.

Pictet Asset Management (Switzerland) held 1,027,977 shares of Denali Therapeutics worth $30.3M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 220,513 Denali Therapeutics shares in Q2 2023, an estimated $6.2M.
Denali Therapeutics made up 0.04% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #373 holding.
Pictet Asset Management (Switzerland) first reported a position in Denali Therapeutics in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s Denali Therapeutics position peaked at $44.5M in Q4 2021.
203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.